About Phathom Pharmaceuticals
Phathom Pharmaceuticals is a company based in Menlo Park (United States) founded in 2019 by David Socks.. Phathom Pharmaceuticals has raised $90 million across 2 funding rounds from investors including SVB, Janus Henderson Investors and RA Capital. The company has 427 employees as of December 31, 2024. Phathom Pharmaceuticals offers products and services including VOQUEZNA. Phathom Pharmaceuticals operates in a competitive market with competitors including VectivBio, Guangzhou Zhiyi Pharmaceutics, Lumena Pharma, Kamui Pharma and Ellodi Pharmaceuticals, among others.
- Headquarter Menlo Park, United States
- Employees 427 as on 31 Dec, 2024
- Founders David Socks
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Phathom Pharmaceuticals, Inc.
-
Annual Revenue
$55.25 M8001.47as on Dec 31, 2024
-
Net Profit
$-334.33 M-65.84as on Dec 31, 2024
-
EBITDA
$-276.67 M-65.93as on Dec 31, 2024
-
Total Equity Funding
$90 M (USD)
in 2 rounds
-
Latest Funding Round
$90 M (USD), Series C
May 15, 2019
-
Investors
SVB
& 9 more
-
Employee Count
427
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Phathom Pharmaceuticals
Phathom Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol PHAT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Phathom Pharmaceuticals
Phathom Pharmaceuticals offers a comprehensive portfolio of products and services, including VOQUEZNA. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats acid-related damage and heartburn for GI disorders in adults.
Unlock access to complete
Unlock access to complete
Funding Insights of Phathom Pharmaceuticals
Phathom Pharmaceuticals has successfully raised a total of $90M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $90 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series C — $90.0M
-
First Round
First Round
(15 May 2019)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2019 | Amount | Debt – Conventional - Phathom Pharmaceuticals | Valuation |
investors |
|
| May, 2019 | Amount | Series C - Phathom Pharmaceuticals | Valuation | Frazier Healthcare Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Phathom Pharmaceuticals
Phathom Pharmaceuticals has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Janus Henderson Investors and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage life science focused VC firm investing in geographies such as Europe and the US
|
Founded Year | Domain | Location | |
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
Diversified investment management firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Phathom Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Phathom Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Phathom Pharmaceuticals Comparisons
Competitors of Phathom Pharmaceuticals
Phathom Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as VectivBio, Guangzhou Zhiyi Pharmaceutics, Lumena Pharma, Kamui Pharma and Ellodi Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Transformative therapeutics for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Second-generation probiotics are developed for gastrointestinal disorders.
|
|
| domain | founded_year | HQ Location |
Passionately pursuing better treatments for adults and children with rare liver diseases.
|
|
| domain | founded_year | HQ Location |
Probiotic medicines for treating gastrointestinal diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for Eosinophilic Esophagitis are developed by Ellodi Pharmaceuticals.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Phathom Pharmaceuticals
Frequently Asked Questions about Phathom Pharmaceuticals
When was Phathom Pharmaceuticals founded?
Phathom Pharmaceuticals was founded in 2019.
Where is Phathom Pharmaceuticals located?
Phathom Pharmaceuticals is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Who is the current CEO of Phathom Pharmaceuticals?
David Socks is the current CEO of Phathom Pharmaceuticals. They have also founded this company.
Is Phathom Pharmaceuticals a funded company?
Phathom Pharmaceuticals is a funded company, having raised a total of $90M across 2 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $50M, raised on May 15, 2019.
How many employees does Phathom Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Phathom Pharmaceuticals is 427.
What is the annual revenue of Phathom Pharmaceuticals?
Annual revenue of Phathom Pharmaceuticals is $55.25M as on Dec 31, 2024.
What does Phathom Pharmaceuticals do?
Phathom Pharmaceuticals was founded in 2019 and is based in Menlo Park, United States. Operations are centered in the pharmaceutical sector, where gastrointestinal disease treatments are developed. The lead candidate, Vonoprazana potassium-competitive acid blockeris targeted at gastroesophageal reflux disease and erosive esophagitis, with phase II clinical trials completed. Leadership includes David Socks as co-founder and CEO, alongside Terrie Curran as CEO and president.
Who are the top competitors of Phathom Pharmaceuticals?
Phathom Pharmaceuticals's top competitors include VectivBio, Lumena Pharma and Guangzhou Zhiyi Pharmaceutics.
What products or services does Phathom Pharmaceuticals offer?
Phathom Pharmaceuticals offers VOQUEZNA.
Is Phathom Pharmaceuticals publicly traded?
Yes, Phathom Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol PHAT.
Who are Phathom Pharmaceuticals's investors?
Phathom Pharmaceuticals has 10 investors. Key investors include SVB, Janus Henderson Investors, RA Capital, Frazier Healthcare Partners, and Abingworth.
What is Phathom Pharmaceuticals's ticker symbol?
The ticker symbol of Phathom Pharmaceuticals is PHAT on NASDAQ.